Role of ccfDNA-based biomarkers in classification of adrenocortical adenomas
Mengjie Xu(Guizhou Minzu University), Cristina L. Ronchi(University of Birmingham), Yasir Elhassan(University Hospitals Birmingham NHS Foundation Trust), David S. Tourigny(University of Birmingham), Miriam Asia(University Hospitals Birmingham NHS Foundation Trust), Ana Crastin(University of Birmingham), Silke Appenzeller(Comprehensive Cancer Center Mainfranken), Juliane Lippert(University of Würzburg), Oskar Podstawka(University of Birmingham), Alessandro Prete(HealthPartners), Kassiani Skordilis(Queen Elizabeth Hospital Birmingham)
Cited by 1
Related Papers
Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome
|New England Journal of Medicine|2014|434
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
|The Journal of Clinical Endocrinology & Metabolism|2010|374
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
|Annals of Oncology|2015|257
Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess
|Annals of Internal Medicine|2019|247
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study
|The Lancet Diabetes & Endocrinology|2020|247